HDAC inhibitor-based therapies: can we interpret the code?
Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone dea...
Հիմնական հեղինակներ: | New, M, Olzscha, H, La Thangue, N |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2012
|
Նմանատիպ նյութեր
-
The TLR adaptor protein MyD88 mediates cell sensitivity to HDAC inhibitors through a cytokine-dependent mechanism
: Sheikh, S, և այլն
Հրապարակվել է: (2016) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
: New, M, և այլն
Հրապարակվել է: (2013) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
: New, M, և այլն
Հրապարակվել է: (2013) -
HDAC inhibitor-based therapies and haematological malignancy.
: Stimson, L, և այլն
Հրապարակվել է: (2009) -
TLR adaptor protein MYD88 mediates sensitivity to HDAC inhibitors via a cytokine-dependent mechanism
: New, M, և այլն
Հրապարակվել է: (2016)